A Study of SGN-B6A in Advanced Solid Tumors

  • STATUS
    Recruiting
  • End date
    Nov 30, 2023
  • participants needed
    285
  • sponsor
    Seagen Inc.
Updated on 23 August 2021
cancer
measurable disease
carcinoma
breast cancer
squamous cell carcinoma
lung cancer
pancreatic adenocarcinoma
esophageal cancer
HER2
gastric cancer
adenocarcinoma
solid tumour
ovarian cancer
erbb2
bladder cancer
esophagus cancer
bladder tumor
her2/neu-negative breast cancer
cancer, ovarian
cancer of the ovary
lung carcinoma

Summary

This trial will look at a drug called SGN-B6A to find out whether it is safe for people who have solid tumors. It will study SGN-B6A to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether SGN-B6A works to treat solid tumors.

The study will have two parts. Part A of the study will find out how much SGN-B6A should be given to participants. Part B will use the dose found in Part A to find out how safe SGN-B6A is and if it works to treat solid tumors.

Details
Condition Non-Small Cell Lung Cancer, Cervical Cancer, urinary tract neoplasm, Ovarian disorder, Disorders of cervix NOS, Uterine Cancer, bladder cancer, bladder disorder, Breast Cancer, Ovarian Cancer, Esophageal Diseases, Esophageal Cancer, Squamous cell carcinoma, Gastropathy, Gastric Cancer, head and neck cancer, Stomach Discomfort, Ovarian Function, Esophageal Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Breast Cancer Diagnosis, Esophageal Squamous Cell Carcinoma, Urothelial Cancer, Squamous Cell Carcinoma of Head and Neck, Squamous Cell Carcinoma of Esophagus, Gastric Carcinoma, Head and Neck Squamous Cell Cancer, Recurrent Ovarian Cancer, Esophageal Disorders, Stomach Cancer, Bladder Disorders, Bladder Carcinoma, Urologic Cancer, Cutaneous Squamous Cell Cancer, Exocrine Pancreatic Adenocarcinoma, breast carcinoma, cervical carcinoma, gastric neoplasm, ovarian carcinomas, cancer, ovarian, cancer ovarian, cancer of the ovary, gastric cancers, carcinoma of the bladder, cancer, breast, esophagus cancer, oesophageal cancer, gastric tumor, nsclc, breast tumors, tumor of the breast, breast tumor, cervical cancer, uterine, carcinoma of the cervix uteri, carcinoma of the cervix, cervix cancer, cancer of the cervix, carcinoma of cervix, ovarian tumors, cervical neoplasm, cancer of the esophagus, oesophageal carcinoma, bladder tumor
Treatment SGN-B6A
Clinical Study IdentifierNCT04389632
SponsorSeagen Inc.
Last Modified on23 August 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Disease indication
Participants must have histologically or cytologically confirmed metastatic or unresectable solid malignancy within one of the tumor types listed below (dependent on study part). Participants must have disease that is relapsed or refractory or be intolerant to standard-of-care therapies and should have no appropriate standard-of-care therapeutic option
Non-small cell lung cancer (NSCLC)
Head and neck squamous cell cancer (HNSCC)
Advanced HER2-negative breast cancer
Esophageal squamous cell carcinoma (ESCC)
Cutaneous squamous cell cancer (cSCC)
Exocrine pancreatic adenocarcinoma
Bladder cancer
Cervical cancer
Gastric cancer
High grade serous ovarian cancer (HGSOC)
Participants enrolled in the following study parts should have a tumor site accessible for biopsy and agree to biopsy as follows
Disease-specific expansion cohorts, participant 13 onwards: pre-treatment biopsy
Biology expansion cohort: pre-treatment biopsy and additional on-treatment biopsy during Cycle 1
An Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
Measurable disease per the RECIST v1.1 at baseline

Exclusion Criteria

History of another malignancy within 3 years before first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death
Known active central nervous system metastases. Participants with previously treated brain metastases may participate provided they
are clinically stable for at least 4 weeks prior to study entry after brain metastasis treatment
have no new or enlarging brain metastases, and
are off of corticosteroids prescribed for symptoms associated with brain metastases for at least 7 days prior to first dose of study drug
Carcinomatous meningitis
Previous receipt of an MMAE-containing agent or an agent targeting integrin beta-6
Pre-existing neuropathy Grade 2 or greater per the National Cancer Institute's Common Terminology Criteria for Adverse Events, version 5.0 (NCI CTCAE v5.0)
Any uncontrolled Grade 3 or higher (per NCI CTCAE v5.0) viral, bacterial, or fungal infection within 2 weeks prior to the first dose of SGN-B6A
Routine antimicrobial prophylaxis is permitted
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note